PURPOSE: The association of Ki-67 staining index (Ki67-SI) with overall survival (OS), disease-specific mortality (DSM), distant metastasis (DM), and biochemical failure (BF) was examined in men with favorable- to intermediate-risk prostate cancer receivingradiation therapy (RT) alone or with short-term androgen deprivation (ADT) in Radiation Therapy Oncology Group (RTOG) 94-08. METHODS AND MATERIALS: 468 patients (23.6%) on RTOG 94-08 had sufficient tissue for Ki67-SI analysis. The median follow-up time was 7.9 years. Ki67-SI was determined by immunohistochemistry and quantified manually and by image analysis. Correlative analysis versus clinical outcome was performed using the third quartile (≥Q3) cutpoint. A proportional hazards multivariable analysis (MVA) dichotomized covariates in accordance with trial stratification and randomization criteria. RESULTS: In MVAs adjusted for all treatment covariates, high Ki67-SI (≥Q3) was correlated with increased DSM (hazard ratio [HR] 2.48, P=.03), DM (HR 3.5, P=.002), and BF (HR 3.55, P<.0001). MVA revealed similar Ki67-associated hazard ratios in each separate treatment arm for DSM, DM, and BF; these reached significance only for DM in the RT-alone arm and for BF in both arms. Ki67-SI was not a significant predictor of intraprostatic recurrence assessed by repeated biopsy 2 years after treatment. Patients with a high or low Ki67-SI seemed to experience a similar relative benefit from the addition of ADT to radiation. CONCLUSIONS: High Ki67-SI independently predicts for increased DSM, DM, and protocol BF in primarily intermediate-risk prostate cancer patients treated with RT with or without ADT on RTOG 94-08 but does not predict for local recurrence or for increased relative benefit from ADT. This and prior studies lend support for the use of Ki67-SI as a stratification factor in future trials.
RCT Entities:
PURPOSE: The association of Ki-67 staining index (Ki67-SI) with overall survival (OS), disease-specific mortality (DSM), distant metastasis (DM), and biochemical failure (BF) was examined in men with favorable- to intermediate-risk prostate cancer receiving radiation therapy (RT) alone or with short-term androgen deprivation (ADT) in Radiation Therapy Oncology Group (RTOG) 94-08. METHODS AND MATERIALS: 468 patients (23.6%) on RTOG 94-08 had sufficient tissue for Ki67-SI analysis. The median follow-up time was 7.9 years. Ki67-SI was determined by immunohistochemistry and quantified manually and by image analysis. Correlative analysis versus clinical outcome was performed using the third quartile (≥Q3) cutpoint. A proportional hazards multivariable analysis (MVA) dichotomized covariates in accordance with trial stratification and randomization criteria. RESULTS: In MVAs adjusted for all treatment covariates, high Ki67-SI (≥Q3) was correlated with increased DSM (hazard ratio [HR] 2.48, P=.03), DM (HR 3.5, P=.002), and BF (HR 3.55, P<.0001). MVA revealed similar Ki67-associated hazard ratios in each separate treatment arm for DSM, DM, and BF; these reached significance only for DM in the RT-alone arm and for BF in both arms. Ki67-SI was not a significant predictor of intraprostatic recurrence assessed by repeated biopsy 2 years after treatment. Patients with a high or low Ki67-SI seemed to experience a similar relative benefit from the addition of ADT to radiation. CONCLUSIONS: High Ki67-SI independently predicts for increased DSM, DM, and protocol BF in primarily intermediate-risk prostate cancerpatients treated with RT with or without ADT on RTOG 94-08 but does not predict for local recurrence or for increased relative benefit from ADT. This and prior studies lend support for the use of Ki67-SI as a stratification factor in future trials.
Authors: Christopher U Jones; Daniel Hunt; David G McGowan; Mahul B Amin; Michael P Chetner; Deborah W Bruner; Mark H Leibenhaut; Siraj M Husain; Marvin Rotman; Luis Souhami; Howard M Sandler; William U Shipley Journal: N Engl J Med Date: 2011-07-14 Impact factor: 91.245
Authors: Thomas J Sebo; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Robert P Myers; Michael L Blute; Horst Zincke Journal: Am J Surg Pathol Date: 2002-04 Impact factor: 6.394
Authors: Didier Cowen; Patricia Troncoso; Vincent S Khoo; Gunar K Zagars; Andrew C von Eschenbach; Marvin L Meistrich; Alan Pollack Journal: Clin Cancer Res Date: 2002-05 Impact factor: 12.531
Authors: Li Yan Khor; Jennifer Moughan; Tahseen Al-Saleem; Elizabeth H Hammond; Varagur Venkatesan; Seth A Rosenthal; Mark A Ritter; Howard M Sandler; Gerald E Hanks; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2007-06-15 Impact factor: 12.531
Authors: Rile Li; Kateri Heydon; M Elizabeth Hammond; David J Grignon; Mack Roach; Harvey B Wolkov; Howard M Sandler; William U Shipley; Alan Pollack Journal: Clin Cancer Res Date: 2004-06-15 Impact factor: 12.531
Authors: Alan Pollack; Didier Cowen; Patricia Troncoso; Gunar K Zagars; Andrew C von Eschenbach; Marvin L Meistrich; Timothy McDonnell Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: A Pollack; M DeSilvio; L-Y Khor; R Li; T I Al-Saleem; M E Hammond; V Venkatesan; C A Lawton; M Roach; W U Shipley; G E Hanks; H M Sandler Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: Michael T Marrone; Corinne E Joshu; Sarah B Peskoe; Angelo M De Marzo; Christopher M Heaphy; Shawn E Lupold; Alan K Meeker; Elizabeth A Platz Journal: Clin Chem Date: 2018-12-05 Impact factor: 8.327
Authors: Joseph J Fantony; Lauren E Howard; Ilona Csizmadi; Andrew J Armstrong; Amy L Lark; Colette Galet; William J Aronson; Stephen J Freedland Journal: Biomark Med Date: 2018-06-15 Impact factor: 2.851
Authors: Alan Pollack; Deukwoo Kwon; Gail Walker; Li Yan Khor; Eric M Horwitz; Mark K Buyyounouski; Radka Stoyanova Journal: J Natl Cancer Inst Date: 2017-02-01 Impact factor: 13.506
Authors: M S Tretiakova; W Wei; H D Boyer; L F Newcomb; S Hawley; H Auman; F Vakar-Lopez; J K McKenney; L Fazli; J Simko; D A Troyer; A Hurtado-Coll; I M Thompson; P R Carroll; W J Ellis; M E Gleave; P S Nelson; D W Lin; L D True; Z Feng; J D Brooks Journal: Prostate Cancer Prostatic Dis Date: 2016-05-03 Impact factor: 5.554